Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Silence Therapeutics Plc - American Depository Share
(NQ:
SLN
)
13.97
+0.39 (+2.87%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Silence Therapeutics Plc - American Depository Share
< Previous
1
2
3
4
5
6
Next >
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference
November 12, 2025
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 06, 2025
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
October 23, 2025
From
Silence Therapeutics plc
Via
Business Wire
Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings)
↗
March 04, 2025
Via
Benzinga
Earnings Scheduled For February 27, 2025
↗
February 27, 2025
Via
Benzinga
Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings)
↗
February 03, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
October 21, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
October 21, 2025
Via
Benzinga
Silence Therapeutics to Participate in September Investor Conferences
September 02, 2025
From
Silence Therapeutics plc
Via
Business Wire
Silence (SLN) Q2 Revenue Drops 71%
↗
August 07, 2025
Via
The Motley Fool
The Analyst Landscape: 6 Takes On Silence Therapeutics
↗
December 10, 2024
Via
Benzinga
Analyst Scoreboard: 4 Ratings For Silence Therapeutics
↗
November 15, 2024
Via
Benzinga
Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
August 07, 2025
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera
June 12, 2025
From
Silence Therapeutics plc
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
June 03, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 13, 2025
Via
Benzinga
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 08, 2025
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
May 06, 2025
From
Silence Therapeutics plc
Via
Business Wire
These stocks are moving in today's pre-market session
↗
April 01, 2025
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
Via
Chartmill
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
March 05, 2025
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
February 27, 2025
From
Silence Therapeutics plc
Via
Business Wire
Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 15
↗
February 15, 2025
What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 10-14, 2025.
Via
Talk Markets
Topics
Stocks / Equities
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
February 13, 2025
From
Silence Therapeutics plc
Via
Business Wire
This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
↗
February 11, 2025
Via
Benzinga
Top 3 Health Care Stocks That May Explode In Q4
↗
December 18, 2024
Via
Benzinga
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
December 09, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
↗
November 19, 2024
Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges.
Via
Benzinga
Top 3 Health Care Stocks You'll Regret Missing In Q4
↗
November 19, 2024
Via
Benzinga
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
November 18, 2024
From
Silence Therapeutics plc
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
